Abstract:Integrins are considered the main cell-adhesion transmembrane receptors that play multifaceted roles as extracellular matrix (ECM)-cytoskeletal linkers and transducers in biochemical and mechanical signals between cells and their environment in a wide range of states in health and diseases. Integrin functions are dependable on a delicate balance between active and inactive status via multiple mechanisms, including protein-protein interactions, conformational changes, and trafficking. Due to their exposure on the cell surface and sensitivity to the molecular blockade, integrins have been investigated as pharmacological targets for nearly 40 years, but given the complexity of integrins and sometimes opposite characteristics, targeting integrin therapeutics has been a challenge. To date, only seven drugs targeting integrins have been successfully marketed, including abciximab, eptifibatide, tirofiban, natalizumab, vedolizumab, lifitegrast, and carotegrast. Currently, there are approximately 90 kinds of integrin-based therapeutic drugs or imaging agents in clinical studies, including small molecules, antibodies, synthetic mimic peptides, antibody–drug conjugates (ADCs), chimeric antigen receptor (CAR) T-cell therapy, imaging agents, etc. A serious lesson from past integrin drug discovery and research efforts is that successes rely on both a deep understanding of integrin-regulatory mechanisms and unmet clinical needs. Herein, we provide a systematic and complete review of all integrin family members and integrin-mediated downstream signal transduction to highlight ongoing efforts to develop new therapies/diagnoses from bench to clinic. In addition, we further discuss the trend of drug development, how to improve the success rate of clinical trials targeting integrin therapies, and the key points for clinical research, basic research, and translational research.

Targeting integrin pathways: mechanisms and advances in therapy

Targeting Fusion Proteins of the Interleukin Family: A Promising New Strategy for the Treatment of Autoinflammatory Diseases.

Roles of integrin in tumor development and the target inhibitors.

From Basic Research to Clinical Implications

Novel Ligands Targeting α4β1 Integrin: Therapeutic Applications and Perspectives

Integrins in cancer: Emerging mechanisms and therapeutic opportunities

The Role of Integrins for Mediating Nanodrugs to Improve Performance in Tumor Diagnosis and Treatment

Integrins as attractive targets for cancer therapeutics

Integrins in Health and Disease—Suitable Targets for Treatment?

The Challenges and Opportunities of Αvβ3-Based Therapeutics in Cancer: from Bench to Clinical Trials

Conjecturing about Small-Molecule Agonists and Antagonists of α4β1 Integrin: From Mechanistic Insight to Potential Therapeutic Applications

Integrin-Targeting Peptides for the Design of Functional Cell-Responsive Biomaterials

Integrin signaling in cancer: bidirectional mechanisms and therapeutic opportunities

Development of Integrin Inhibitors in Antitumor Therapy

The challenges and opportunities of alpha v beta 3-based therapeutics in cancer: From bench to clinical trials

Unraveling the molecular basis for effective regulation of integrin α5β1 for enhanced therapeutic interventions

Alpha(4)Beta(7) Integrin Inhibitors: A Patent Review

Nanocarrier Based Targeting of Vascular Cell Adhesion Molecule-1 for Diagnosis and Treatment of Atherosclerosis: Current Status and Future Perspectives

Small molecule– and peptide–drug conjugates addressing integrins: A story of targeted cancer treatment

Α4β7 Integrin Inhibitors: a Patent Review.

Integrins regulate stemness in solid tumor: an emerging therapeutic target